
    
      This is a randomized clinical trial that assigns patients with female breast cancer in the
      metastatic entity or advanced -beyond local disease treatment - entity into two arms. Arm A
      contains Letrozole with metronomic Capecitabine versus arm B that contains Letrozole alone.
      This is to be applied on ER positive HER2 negative tumours.
    
  